Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07541404 · ClinicalTrials.gov registry record · NA
MMA Embolization With NeoCast for Subacute and Chronic Subdural Hematoma
A NA study, sponsored by Arsenal Medical.
- Not yet
- Registry status
- NA
- Development phase
- 360
- Enrollment target
NCT07541404 is a NA study that has not yet begun recruiting, run by Arsenal Medical. The registered enrollment target is 360 participants.
The verdict
NCT07541404, a NA study, has not yet begun recruiting, sponsored by Arsenal Medical.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 360 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of embolization of the middle meningeal artery (MMA) using the NeoCast Embolic System for treatment of symptomatic subacute or chronic subdural hematoma (SDH) adjunctive to surgery.
Interventions
- DEVICE NeoCast Embolic System
- DEVICE Onyx LES, an FDA-Approved Commercial Liquid Embolic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07541404
The ClinicalTrials.gov registry entry for NCT07541404 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arsenal Medical, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which NeoCast Embolic System is the first listed.
NCT07541404 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07541404 about?
NCT07541404 is a clinical study titled "MMA Embolization With NeoCast for Subacute and Chronic Subdural Hematoma". The purpose of this study is to evaluate the safety and efficacy of embolization of the middle meningeal artery (MMA) using the NeoCast Embolic System for treatment of symptomatic subacute or chronic subdural hematoma (SDH) adjunctive to surgery.
What is the current status of trial NCT07541404?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 360 participants. The study started on 2026-07. Estimated completion is 2028-04.
What interventions are being tested in trial NCT07541404?
The interventions under investigation include: NeoCast Embolic System (DEVICE), Onyx LES, an FDA-Approved Commercial Liquid Embolic (DEVICE).
Who is sponsoring clinical trial NCT07541404?
This trial is sponsored by Arsenal Medical, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.